Latanoprost for the treatment of pediatric glaucoma

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Enyedi, Laura B ^a   Freedman, Sharon F ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Children; Latanoprost; Ocular hypertension; Open angle glaucoma

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; LATANOPROST; PROSTAGLANDIN F2 ALPHA; TIMOLOL;

ALLERGIC REACTION; APHAKIA; ARTICLE; CLINICAL TRIAL; CONGENITAL GLAUCOMA; CONJUNCTIVA DISEASE; CORNEA THICKNESS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EFFUSION; EYE COLOR; EYE IRRITATION; EYELASH; GLAUCOMA SURGERY; HUMAN; HYPEREMIA; HYPERPIGMENTATION; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; MUSCLE HYPOTONIA; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PUBLICATION; RASH; RETINA MACULA CYSTOID EDEMA; SIDE EFFECT; SLEEP DISORDER; STURGE WEBER SYNDROME; SWEATING; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UVEITIS;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; GLAUCOMA, OPEN-ANGLE; HUMANS; INFANT; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SAFETY; TREATMENT OUTCOME;

EID: 0036669291     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00303-X     Document Type: Article

References (26)

1. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 102:1995;1743-1752.
2. Alphen G.W., Wilhelm P.B., Elsenfeld P.W. The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man. Doc Ophthalmol. 42:1977;397-415.
3. Altuna J.C., Greenfield D.S., Wand M.et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: Benefits and side-effects J Glaucoma. 8:1999;199-203.
4. Brown S.M. Increased iris pigment in a child due to latanoprost. Arch Ophthalmol. 116:1998;1683-1684.
5. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group Ophthalmology. 103:1996;138-147.
6. Enyedi L.B., Freedman S.F., Buckley E.G. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS. 3:1999;33-39.
7. Gabelt B.T., Kaufman P.L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 49:1989;389-402.
8. Hoyng P.F., Rulo A., Greve E.et al. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol. 41(Suppl):1997;S93-S98.
9. Johnstone M.A. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 124:1997;544-547.
10. Kashiwagi K., Lindsey J., Kashiwagi F., Weinreb R. Extracellular matrix changes induced by prostaglandins in cultured human ciliary muscle cells. Invest Ophthalmol Vis Sci. 36(Suppl):1995;S729. [abstract].
11. Kupfer C., Kaiser-Kupfer M.I. Observations on the development of the anterior chamber angle with reference to the pathogenesis of congenital glaucomas. Am J Ophthalmol. 88:1979;424-426.
12. Lusky M., Ticho U., Glovinsky J.et al. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure. Ophthalmology. 104:1997;1720-1724.
13. Lutjen-Drecoll E., Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 47:1988;761-769.
14. Maumenee A.E. Further observations on the pathogenesis of congenital glaucoma. Am J Ophthalmol. 55:1963;1163-1176.
15. Mishima H.K., Masuda K., Kitazawa Y.et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 114:1996;929-932.
16. Nilsson S.F., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 48:1989;707-716.
17. Patelska B., Greenfield D.S., Liebmann J.M.et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 124:1997;279-286.
18. Poyer J.F., Millar C., Kaufman P.L. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 36:1995;2461-2465.
19. Rowe J.A., Hattenhauer M.G., Herman D.C. Adverse side effects associated with latanoprost. Am J Ophthalmol. 124:1997;683-685.
20. Rulo A.H., Greve E.L., Geijssen H.C., Hoyng P.F. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 103:1996;1276-1282.
21. Schmidtborn F: [Systemic side-effects of latanoprost in a child with aniridia and glaucoma]. Ophthalmologe 95:633-4, 1998
22. Tamm E, Rittig M, Lutjen-Drecoll E: [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha]. Fortschr Ophthalmol 87:623-9, 1990
23. Toris C.B., Camras C.B., Yablonski M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1993;1297-1304.
24. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 115:1997;1206-1208.
25. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 103:1996;126-137.
26. Yang C.B., Freedman S.F., Myers J.S.et al. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol. 126:1998;600-602.